BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8005584)

  • 21. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
    Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
    Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line.
    Chow VT; Quek HH; Tock EP
    Cancer Lett; 1993 Sep; 73(2-3):141-8. PubMed ID: 8221626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
    Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
    Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An abundance of p53 null mutations in ovarian carcinoma.
    Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
    Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
    Niwa K; Itoh M; Murase T; Morishita S; Itoh N; Mori H; Tamaya T
    Br J Cancer; 1994 Dec; 70(6):1191-7. PubMed ID: 7981076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
    Reiter RE; Anglard P; Liu S; Gnarra JR; Linehan WM
    Cancer Res; 1993 Jul; 53(13):3092-7. PubMed ID: 8319216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry.
    Kappes S; Milde-Langosch K; Kressin P; Passlack B; Dockhorn-Dworniczak B; Röhlke P; Löning T
    Int J Cancer; 1995 Feb; 64(1):52-9. PubMed ID: 7665249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 mutations in ovarian cancer: a late event?
    Mazars R; Pujol P; Maudelonde T; Jeanteur P; Theillet C
    Oncogene; 1991 Sep; 6(9):1685-90. PubMed ID: 1923532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques.
    Neubauer A; He M; Schmidt CA; Huhn D; Liu ET
    Leukemia; 1993 Apr; 7(4):593-600. PubMed ID: 8464238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.
    Kelley MJ; Nakagawa K; Steinberg SM; Mulshine JL; Kamb A; Johnson BE
    J Natl Cancer Inst; 1995 May; 87(10):756-61. PubMed ID: 7563154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 expression, mutation, and allelic deletion in ovarian cancer.
    McManus DT; Yap EP; Maxwell P; Russell SE; Toner PG; McGee JO
    J Pathol; 1994 Nov; 174(3):159-68. PubMed ID: 7823248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma.
    Quezado MM; Moskaluk CA; Bryant B; Mills SE; Merino MJ
    Hum Pathol; 1999 Feb; 30(2):203-7. PubMed ID: 10029450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A unique p53 intragenic deletion flanked by short direct repeats results in loss of mRNA expression in a human esophageal carcinoma.
    Huang Y; Yin J; Meltzer SJ
    Carcinogenesis; 1994 Aug; 15(8):1653-5. PubMed ID: 8055646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid sequencing of the p53 gene with a new automated DNA sequencer.
    Bharaj BS; Angelopoulou K; Diamandis EP
    Clin Chem; 1998 Jul; 44(7):1397-403. PubMed ID: 9665415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer.
    Brachman DG; Graves D; Vokes E; Beckett M; Haraf D; Montag A; Dunphy E; Mick R; Yandell D; Weichselbaum RR
    Cancer Res; 1992 Sep; 52(17):4832-6. PubMed ID: 1324797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
    Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
    Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment and characterization of human ovarian carcinoma cell lines.
    Yuan Y; Kim WH; Han HS; Lee JH; Park HS; Chung JK; Kang SB; Park JG
    Gynecol Oncol; 1997 Sep; 66(3):378-87. PubMed ID: 9299249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 gene alterations in human prostate carcinoma.
    Effert PJ; McCoy RH; Walther PJ; Liu ET
    J Urol; 1993 Jul; 150(1):257-61. PubMed ID: 8510267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.